Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.Pharmacol Ther. 2008 Jan; 117(1):77-93.P&T
Abstract
Multiple sclerosis (MS) is an autoimmune, neurological disability with unknown etiology. The current therapies available for MS work by an immunomodulatory action, preventing T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and axonal loss. Recently, FTY720 (fingolimod) was shown to significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials. This drug attenuates trafficking of harmful T cells entering the brain by regulating sphingosine-1-phosphate (S1P) receptors. Here, we outline the direct roles that S1P receptors play in the central nervous system (CNS) and discuss additional modalities by which FTY720 may provide direct neuroprotection in MS.
Links
MeSH
Pub Type(s)
Journal Article
Review
Language
eng
PubMed ID
17961662
Citation
Dev, Kumlesh K., et al. "Brain Sphingosine-1-phosphate Receptors: Implication for FTY720 in the Treatment of Multiple Sclerosis." Pharmacology & Therapeutics, vol. 117, no. 1, 2008, pp. 77-93.
Dev KK, Mullershausen F, Mattes H, et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol Ther. 2008;117(1):77-93.
Dev, K. K., Mullershausen, F., Mattes, H., Kuhn, R. R., Bilbe, G., Hoyer, D., & Mir, A. (2008). Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacology & Therapeutics, 117(1), 77-93.
Dev KK, et al. Brain Sphingosine-1-phosphate Receptors: Implication for FTY720 in the Treatment of Multiple Sclerosis. Pharmacol Ther. 2008;117(1):77-93. PubMed PMID: 17961662.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
AU - Dev,Kumlesh K,
AU - Mullershausen,Florian,
AU - Mattes,Henri,
AU - Kuhn,Rainer R,
AU - Bilbe,Graeme,
AU - Hoyer,Daniel,
AU - Mir,Anis,
Y1 - 2007/09/08/
PY - 2007/08/16/received
PY - 2007/08/16/accepted
PY - 2007/10/27/pubmed
PY - 2008/3/12/medline
PY - 2007/10/27/entrez
SP - 77
EP - 93
JF - Pharmacology & therapeutics
JO - Pharmacol Ther
VL - 117
IS - 1
N2 - Multiple sclerosis (MS) is an autoimmune, neurological disability with unknown etiology. The current therapies available for MS work by an immunomodulatory action, preventing T-cell- and macrophage-mediated destruction of brain-resident oligodendrocytes and axonal loss. Recently, FTY720 (fingolimod) was shown to significantly reduce relapse rates in MS patients and is currently in Phase III clinical trials. This drug attenuates trafficking of harmful T cells entering the brain by regulating sphingosine-1-phosphate (S1P) receptors. Here, we outline the direct roles that S1P receptors play in the central nervous system (CNS) and discuss additional modalities by which FTY720 may provide direct neuroprotection in MS.
SN - 0163-7258
UR - https://www.unboundmedicine.com/medline/citation/17961662/Brain_sphingosine_1_phosphate_receptors:_implication_for_FTY720_in_the_treatment_of_multiple_sclerosis_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0163-7258(07)00173-8
DB - PRIME
DP - Unbound Medicine
ER -